Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
about
State of the Art: Newer biomarkers in heart failureMacrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infectionPlasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction StudyGalectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo StudyIdentification of candidate long non-coding RNAs in response to myocardial infarction.Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonistsGalectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes.Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices.Galectin-3: a novel biomarker for the prognosis of heart failure.Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites.Cell cycle arrest in a model of colistin nephrotoxicity.Serial galectin-3 and future cardiovascular disease in the general population.Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease.Variability of biomarkers in patients with chronic heart failure and healthy controls.Heart failure biomarkers.Galectin-3 in heart failure with preserved ejection fraction.Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond.The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.Galectin-3: a modifiable risk factor in heart failure.Biomarkers for risk prediction in acute decompensated heart failure.Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.Novel renal biomarkers to assess cardiorenal syndromeLong-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes.Candidate biomarkers in heart failure with reduced and preserved ejection fraction.Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.New Targets in the Drug Treatment of Heart Failure.Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure.Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis.Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.Using galectin-3 to reduce heart failure rehospitalization.Role of Inflammation in Heart Failure.From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities.
P2860
Q27027899-3485AD80-746F-43AF-8E0E-12889BC363DCQ30405402-782B54EF-2D98-4A63-A5B4-478F593FEC7EQ31036336-08AC078A-F13F-410F-A1C5-58AF7A10EB8EQ33577541-DFF0963A-A077-4C5A-86BD-A2AFB91E8F8DQ33805258-AB8C5FD4-4C76-4736-9B9F-A2C8CDA3A2B1Q33912126-8AB02E47-6215-4C08-9DCB-449D2BDD42D4Q35191679-CDE7ED26-1668-49BB-B4D7-84B0CF0DA4C5Q35206146-EF11F3E9-FACF-403A-BFED-F96C917138C3Q35807149-D01B1120-9EFA-4CDD-86C8-D5359700F3A6Q35842591-211D4AB5-6573-406C-8A58-BE8C7C79344EQ36035702-307A3DF5-E201-4E24-AE94-D2AEF79A4130Q36297961-CE5007BF-D352-4101-85D6-963D114D8936Q36385583-F71677BA-EF90-4F6D-967D-634F52FC756CQ36956715-69399AD2-0251-4865-AB88-260F8B0BF411Q37234937-EB923946-82D2-4988-9760-BA5A9A9C0F6CQ37580709-4C328680-3C78-44AD-AE64-DA91D8577CE5Q37681556-3911D778-B3A3-434B-AD07-F9EB98FEBA15Q37696493-D4A2BB9D-A31E-463A-A9CC-12AE24B992B8Q38100647-31802B94-51F9-4923-990E-8822DBF4DB26Q38104695-E5C80479-F89E-4357-85EB-66A0A1AA94FDQ38110226-AAF6A8BF-3179-4708-B7B9-74E909DAB302Q38154222-2A39EE1F-942A-45F6-B2FD-4F1FF216694FQ38173317-EABEBB4D-1C98-4660-8663-48AB8059A447Q38194209-AF6C4D5E-422B-4E3A-896F-532083D6B100Q38208784-8EA6A1A5-9B89-4B47-91E8-4CE007385BDFQ38222370-4C0D6872-DEA9-405B-9BE5-046FDB8A09E1Q38225729-B130BB62-BB34-4974-85E7-DF9AC7D13EF5Q38252731-7A57C5E5-3528-4CB5-A8F1-DA57E8E77D8EQ38426618-5BECF011-A22C-4B6A-AC2A-3776E6BD843FQ38572500-6EF7FB93-0BD4-4458-90AF-B383237BDA21Q38596113-3F7D89CE-7577-4820-B7B9-F7703E392CA3Q38614176-8C742330-3A3A-4E96-A988-A2DC82B7644DQ38663003-0F9F3FCB-9BB5-47D4-BD50-863188CC2B8AQ38667210-2A6AD6C5-B44E-4381-9CE7-04E5268A52BAQ38687046-2A37DB35-62EB-4D6C-B104-303442284516Q38727409-D647DF41-10A4-4ECE-96F3-37B094C0EBE0Q38977493-46A69393-4F2D-4AEE-9A8F-84CDDEF55BDEQ39204234-E2961BE6-9163-45E3-BBD5-8536877A788BQ39255848-8DAE25E0-33FE-4EB9-B57A-CF772B617176Q39434474-4236614A-1193-4FBB-B9EC-8ED9E791A2D4
P2860
Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prognostic value of changes in ...... e: data from CORONA and COACH.
@ast
Prognostic value of changes in ...... e: data from CORONA and COACH.
@en
type
label
Prognostic value of changes in ...... e: data from CORONA and COACH.
@ast
Prognostic value of changes in ...... e: data from CORONA and COACH.
@en
prefLabel
Prognostic value of changes in ...... e: data from CORONA and COACH.
@ast
Prognostic value of changes in ...... e: data from CORONA and COACH.
@en
P2093
P50
P1476
Prognostic value of changes in ...... e: data from CORONA and COACH.
@en
P2093
A Rogier van der Velde
Aram Adourian
Pieter Muntendam
Rudolf A de Boer
P304
P356
10.1161/CIRCHEARTFAILURE.112.000129
P577
2013-02-08T00:00:00Z